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The gammaherpesvirus alcelaphine herpesvirus 1 (AlHV-1) causes malignant catarrhal fever in susceptible
ungulates but infects its natural host, wildebeest, without obvious clinical signs. In tissue culture, AlHV-1 is initially
predominantly cell associated and virulent but on extended culture becomes cell-free and attenuated. We wanted to
determine what changes in protein composition had taken place during the transition from virulent to attenuated
virus in culture. Purified virus preparations were fractionated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, and proteins were analyzed by liquid chromatography-electrospray ionization–tandem mass spec-
trometry. Peptides were identified in serial gel slices by using MASCOT software to interrogate virus-specific and
nonredundant sequence databases. Twenty-three AlHV-1-encoded proteins and six cellular proteins were identified
in the attenuated and virulent viruses. Two polypeptides were detected in only the virulent virus preparations, while
one other protein was found in only the attenuated virus. Two of these virus-specific proteins were identified by a
single peptide, suggesting that these may be low-abundance virion proteins rather than markers of attenuation or
pathogenesis. The results suggest that attenuation of AlHV-1 is not the result of gross changes in the composition
of the virus particle but probably due to altered viral gene expression in the infected cell.
Malignant catarrhal fever (MCF) is an important, sporadic,
and usually fatal lymphoproliferative disease of cattle and
other susceptible ungulates. MCF is caused by either of two
closely related gammaherpesviruses, alcelaphine herpesvirus 1
(AlHV-1) and ovine herpesvirus 2 (OvHV-2), that belong to
the genus Rhadinovirus (28). These viruses are carried asymp-
tomatically by their natural hosts, the wildebeest (Con-
nochaetes taurinus) in the case of AlHV-1 and the domestic
sheep (Ovis aries) in the case of OvHV-2. Transmission of
these viruses to MCF-susceptible species can give rise to wilde-
beest-associated MCF (26) and sheep-associated MCF, respec-
tively (7, 36).
AlHV-1, the causative agent of WA-MCF, can be propa-
gated in cell culture where, in early passage, virulent virus
particles can be obtained. The prolonged passage of AlHV-1 in
culture, however, causes genomic rearrangements that result in
the production of a cell-free form of the virus that is attenuated
for disease induction (28).
The published annotations of the genomes of AlHV-1 (11)
and OvHV-2 (14) have identified a number of genes that are
common only to the MCF-causing viruses, including the
AlHV-1 open reading frames (ORFs) A7, A8, and A10 that
are predicted to encode glycoproteins that may be found on
the virion.
Comparison of restriction enzyme profiles of the genomes of
virulent and attenuated AlHV-1 strains identified a restriction
fragment (ATT-1) that was found only in the attenuated virus
genome (13). Sequence analysis of ATT-1 showed that it car-
ried the ORF50 gene (homologue of the Epstein-Barr virus
[EBV] lytic cycle regulator, RTA), the A6 gene (a predicted
transcription factor), and a truncated A7 gene fused to se-
quences from the right terminal repeat (37). A range of similar
fragments cloned in the same study showed a common feature
that a central segment of the genome, encoding ORF50, A6,
A7, and A8, was brought into proximity with the right terminal
region, encoding A10, suggesting that such rearrangements
may be a critical feature of the attenuation process. It was
concluded that attenuation of the virus could be associated
with the disruption of the expression of the putative glycopro-
teins A7, A8, and A10 or of the transcription factors encoded
by A6 or ORF50.
The objectives of the present study were (i) to identify the
major components of the AlHV-1 virion, complementing the
existing genome annotation, and (ii) to determine whether
structural differences existed between the attenuated and vir-
ulent forms of AlHV-1. Proteomic analysis of purified virions
has proved to be a successful approach to define the protein
composition of gammaherpesviruses (5, 15, 23, 38). We report
the results of a qualitative proteomic analysis of both virulent
and attenuated AlHV-1 to identify differences that might con-
tribute to the altered pathogenicity of the two forms of the
virus in vivo.
MATERIALS AND METHODS
Cells and viruses. AlHV-1 C500 (27), originally from an MCF-affected cow,
had been isolated and propagated from the spleen of an infected rabbit in
accordance with previously published methodology (13). Bovine turbinate (BT)
cells were cultured in Iscove’s modified Dulbecco’s medium supplemented with
10% (vol/vol) fetal calf serum and 2 mM glutamine, 100 U/ml penicillin, and 100
g/ml streptomycin. AlHV-1 C500 virulent and attenuated strains were propa-
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gated on BT cells cultured in Iscove’s modified Dulbecco’s medium supple-
mented with 2% (vol/vol) fetal calf serum and 2 mM glutamine, 100 U/ml
penicillin and 100 g/ml streptomycin. AlHV-1 C500 strain particles were har-
vested and purified at passage 4 (virulent) or passage 1009 (attenuated). The
attenuated and virulent viruses have been tested in vaccination and challenge
experiments in cattle which showed that only the virulent virus induced MCF
after intranasal or intravenous inoculation (D. Haig, unpublished data).
Purification and isolation of AlHV-1C500. Both virulent and attenuated
AlHV-1 were obtained by a freeze-thaw cycle from infected BT cells, when
virus-induced cytopathic effect reached 100% (at approximately 4 days postin-
fection). Cellular debris was cleared from the lysates by centrifugation at 3,000
g for 15 min at 4°C. The viral particles were pelleted from the supernatant by
centrifugation at 100,000 g for 3 h at 4°C. The resulting pellet was resuspended
in TNE buffer (20 mM Tris [pH 8], 100 mM NaCl, 1 mM EDTA) and loaded
onto a 20 to 55% continuous sucrose gradient to further purify the virus. The
gradient was subjected to centrifugation at 100,000  g for 18 h at 4°C. Virus-
containing fractions from the gradient were identified by Western blotting using
monoclonal antibody 12B5, specific for the main glycoprotein complex of the
virus (1). Positive fractions were pooled and diluted approximately 1:3 in TNE
buffer. The virus particles were then pelleted by centrifugation at 100,000 g for
3 h at 4°C, resuspended in TNE buffer, and frozen at 70°C until used. Virus
preparations were examined by electron microscopy to obtain an indication of
the purity of the virus preparation.
Analysis of virus preparations by electron microscopy. A standardized sus-
pension of 91-nm-mean-diameter polystyrene latex particles (Agar Scientific,
Essex, United Kingdom) at 1010 particles/ml was used for virus particle counting,
based on the method described by Williams and Backus (35). As a precaution
against clumping, the stock suspension was sonicated for 1 min before dilution
and immediately before use.
Equal volumes of virus suspension and latex particle suspension were thor-
oughly mixed, loaded onto a carbon-Formvar grid and placed onto a drop of
2.0% phosphotungstic acid (pH 7.0) for 1 min. Stained grids were viewed in the
electron microscope at a screen magnification of 45,000 and scanned vertically
along the rows of grid squares. Three complete scans were made (one toward
either end and one at the center). All virus particles and latex particles seen
separately or in groups of no more than three during each individual scan were
counted. The ratio of virus particles to latex particles was then calculated for
each scan, and the mean ratio was multiplied by the latex particle concentration
to give the virus particle concentration per milliliter.
SDS-PAGE gel electrophoresis. Purified virions (approximately 3.5  108
particles) were denatured at 100°C for 10 min in sample buffer (Tris-glycine,
sodium dodecyl sulfate [SDS] sample buffer, 1 sample reducing agent; Invitro-
gen, Paisley, United Kingdom) and resolved by SDS-polyacrylamide gel electro-
phoresis (PAGE) on a 10% gel (Invitrogen). Proteins were visualized by staining
with SimplyBlue SafeStain (Invitrogen). A series of gel slices of equal size (2.5
mm), covering the entire sample lane, were excised from the SDS-PAGE gel and
analyzed by liquid chromatography-electrospray ionization–tandem mass spec-
trometry (LC-ESI–MS/MS).
LC-ESI–MS/MS. LC-ESI–MS/MS analysis was carried out essentially as de-
scribed by Batycka et al. (3). Briefly, the proteins within each gel slice excised
from the sample lane were subjected to standard in-gel trypsinolysis. LC was then
performed on samples of 4 l from each gel slice, applied by direct injection into
a monolithic reversed-phase column (200-m inner diameter; Dionex), using an
Ultimate 3000 Nanoflow HPLC system (Dionex-LC Packings). Bound peptides
were eluted in order of increasing hydrophobicity by the application of a 15-min
linear gradient of 8 to 45% acetonitrile in 0.1% formic acid and monitored by
UV absorbance in a 3-nl UV detector flow cell. LC was interfaced with a
three-dimensional high-capacity ion trap mass spectrometer (Esquire HCTplus,
Bruker Daltonics) utilizing a low-volume (50 l/min) stainless steel nebulizer
(Agilent) and ESI. Digests were analyzed for protein content by LC-ESI–MS/MS
in ultrascan mode (26,000 amu/s). MS/MS analysis was initiated on a contact
closure signal triggered by Chromeleon chromatography software (Dionex).
Proteomic analysis of AlHV-1 derived peptides. Peptide spectra were submit-
ted to MASCOT (version 2.1; Matrixscience [25]) and searched against AlHV-
1-specific and NCBI nonredundant protein sequence databases. Generally, pro-
teins were identified by the assignment of at least two peptides with Mascot
Mowse scores of 40 (P  0.0001). Any peptide hits with lower scores were
inspected manually and included in the assignment only if a series of at least four
continuous y or b ions was observed. The identification of any protein based on
a single peptide match was considered reliable only if the protein was identified
in more than one virus preparation.
The relative abundance of individual proteins in the virulent and attenuated
viruses was estimated by comparing the number of peptides identified for each
protein obtained from the different virus preparations.
RESULTS
One of each of the low-pass virulent and high-pass attenu-
ated AlHV-1 virion preparations was analyzed by electron
microscopy to assess the quality of the purified virus. Little
contaminating cellular material was observed in either prepa-
ration. The low-pass AlHV-1 was found to contain 4.43  1010
particles per ml with 5% defective nonenveloped particles,
while the high-pass preparation contained 7.76  109 particles
per ml with 10% defective viruses. Thus, the method used
yielded high-titer, high-quality virus preparations with rela-
tively low contamination with unenveloped virus particles or
nonvirion material.
Proteins from low-pass and high-pass virion preparations
were analyzed by LC-ESI–MS/MS after fractionation by SDS-
PAGE to provide a qualitative picture of virion protein com-
position. The entire analysis procedure was repeated for two
independent virus preparations of virulent and attenuated
AlHV-1 C500. Twenty-three AlHV-1-encoded proteins and six
cellular proteins were identified in the attenuated and virulent
particles. Two virus proteins were detected only in the virulent
virus preparations, while one virus protein was found only in
the attenuated virus (Fig. 1 and Table 1).
Analysis of AlHV-1 virion-associated proteins. (i) Capsid
proteins. The gammaherpesvirus viral capsid is comprised of
four structural proteins encoded by ORF25 (major capsid pro-
tein), ORF62 (triplex-1 protein), ORF26 (triplex-2 protein),
and ORF65 (small capsomer-interacting protein [SCIP]) (18).
In addition, the scaffolding protein, encoded by the 3 end of
ORF17 (termed ORF17.5), is involved in the assembly of the
capsid but is lost when the viral genome is packaged. Variable
amounts of ORF17.5 have been found associated with imma-
ture but not mature forms of the human herpesvirus 8
(HHV-8) virion (21).
In both attenuated and virulent AlHV-1 particles the major
capsid protein, ORF25, appeared to be the most abundant
protein identified, based on the number of peptides detected
(Table 1). The triplex proteins (ORF62 and ORF26) were also
detected in both forms of the virus (Table 1). Interestingly,
ORF65, encoding the SCIP protein, was only detected as a
single peptide in one preparation of attenuated virions but was
identified in matrix-assisted laser desorption ionization–time
of flight analysis of prominent bands in an attenuated virion
preparation fractionated by SDS-PAGE (Mowse score 153
[data not shown]). This may reflect low abundance of the SCIP
protein in AlHV-1 capsids or difficulties in fractionation and/or
ionization of SCIP peptides in the LC-ESI–MS/MS method.
Peptides corresponding to ORF17 were identified in both
attenuated and virulent preparations of AlHV-1. All of the
ORF17 peptides detected corresponded to peptides in the
C-terminal part of the ORF17 sequence and are therefore
probably derived from the scaffold protein ORF17.5. This is
supported by the observation that all ORF17 peptides were
derived from gel bands nearer the predicted size of ORF17.5
(30 kDa) than that of ORF17 (60 kDa) (Fig. 1).
(ii) Glycoproteins. Analysis of the AlHV-1 sequence pre-
dicts that it encodes homologues of the herpesvirus glycopro-
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teins B (gB, ORF8), gH (ORF22), gL (ORF47), gN (ORF53),
and gM (ORF39). In addition, putative glycoproteins are en-
coded by the gammaherpesvirus conserved gene ORF27 and
by the MCF virus-specific genes A7, A8, and A10 (19, 11).
AlHV-1 homologues of gB, gM, gH, and gL were identified in
both the attenuated and the virulent virus preparations (Table
1). Peptides corresponding to gB were isolated from two dis-
tinct gel slices with approximate masses of 80 and 50 kDa,
respectively (Fig. 1). Detailed analysis confirmed that the gB-
specific peptides identified in the 80-kDa gel slice localized to
the N-terminal part of the protein, while peptides in the 50-
kDa gel slice came from the C-terminal portion of gB. Analysis
of the AlHV-1 gB protein sequence identified a furin cleavage
site (RRQR) at the boundary between the two domains (Fig.
2). Supporting evidence for the cleavage of gB was obtained by
matrix-assisted laser desorption ionization–time of flight anal-
ysis of prominent AlHV-1 virion bands extracted from poly-
acrylamide gels (data not shown). The absence of a detectable
signal for full-length gB, found in association with cellular
membranes of other gammaherpesviruses, by MS or Western
blotting (data not shown), is further evidence for the quality of
the virion preparations used in the present study.
Peptides corresponding to gM (44 kDa), ORF27 (35 kDa),
and gL (19 kDa) and the N terminus of gB (50 kDa) were
isolated from gel slices above their predicted masses (Fig. 1).
This is in accord with the predicted glycosylation of these
proteins. Indeed, gM (ORF39) was identified at multiple po-
sitions in both virulent and attenuated virus preparations, at
approximate masses of 35, 80, and 100 kDa. The presence of
the slowest-migrating form may be a consequence of temper-
ature-dependent aggregation which has been observed for the
gM of other herpesviruses (2, 16, 17).
AlHV-1 specific glycoproteins A7, A8, and A10 were among
10 genes in the AlHV-1 genome reported as being “unique” to
this virus (11). Based on the presence of transmembrane regions
and potential glycosylation sites, these proteins have been de-
scribed as putative glycoproteins (8, 11). Of these three proteins,
only A8 was detected in the present study, as a single peptide, in
both preparations of the virulent virus. This peptide was derived
from a gel slice with an estimated mass of 150 kDa (Fig. 1). The
identity of the peptide DENLYVLAQIPALEGHK (residues 272
to 290; Fig. 3) was confirmed by secondary fragmentation, in
which the predicted sequence of the peptide could be inferred
from the masses of multiple adjacent fragmentation ions (n  4
and n 7; Mowse scores of 35 and 55). No peptides correspond-
ing to A7, A8, or A10 were identified from preparations of at-
tenuated C500 particles.
FIG. 1. Protein composition of purified virulent and attenuated forms of the AlHV-1 virus particle. Virulent (lane 2) or attenuated (lane 3)
sucrose-gradient purified virions were resolved on SDS–10% PAGE gels alongside lanes containing SeeBlue Plus2 prestained protein standard
(lanes 1 and 4; Invitrogen). Protein bands were visualized by staining with SimplyBlue SafeStain (Invitrogen). Each lane of the SDS-PAGE gel was
split into 20 equal bands. Proteins in each band were digested in-gel with trypsin and subjected to LC-ESI–MS/MS analysis. MS/MS spectra
matching AlHV-1 proteins and cellular proteins are indicated in each band. An estimate of the size of the identified proteins can be obtained from
the molecular mass markers (lanes 1 and 4).
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(iii) Tegument proteins. The tegument layer is believed to
contain proteins that may be involved in the initiation of virus
infection or in the assembly and morphogenesis of progeny virus.
Based on comparisons with other gammaherpesviruses, 10
AlHV-1 proteins are predicted to belong to the tegument (11,
14). Proteomic analysis of purified virions identified seven of
these proteins (the products of ORFs 3, 19, 33, 38, 63, 64, and 75;
Table 1) as being present in both the attenuated and the virulent
forms of the virus. The other three described tegument proteins
(ORFs 23, 35, and 42) were not reproducibly identified in either
attenuated or virulent particle preparations.
(iv) Nonstructural viral proteins. In the present study, viral
nonstructural proteins were considered putative components of
the virion if relevant peptides could be identified in the analysis of
two independent particle preparations. In both attenuated and
virulent particles, LC-ESI–MS/MS data identified the products of
ORF21 (thymidine kinase), ORF54 (dUTPase), and ORF59
(processivity factor; Table 1) as being putative virion proteins. In
addition, peptides from the ORF10 protein were only found in
the virulent virus particles, while ORF45 was identified only in the
attenuated virus (Table 1).
(v) Cellular proteins. During particle assembly, cellular pro-
teins may be encapsulated into the virion. Peptides from cel-
lular proteins associated with the virus particle were identified
by searching all LC-ESI–MS/MS data against the nonredun-
dant NCBI protein sequence database. Cellular proteins spe-
cifically associated with virus, i.e., identified in at least two
independent particle preparations, included annexins, his-
tones, actin, and pyruvate kinase (Table 1).
DISCUSSION
The aims of this study were twofold: (i) to identify the major
components of the AlHV-1 virion, complementing the existing
TABLE 1. Virus and host proteins associated with attenuated or virulent AlHV-1 virions identified by LC-ESI–MS/MSa
Identified polypeptides
C500b
Attenuated Virulent
AlHV-1 ORF Description Predicted size(kDa)
%
Coverage
No. of
peptides
%
Coverage
No. of
peptides
Glycoproteins
8 N-terminal gB 50 17 6 15 5
8 C-terminal gB 47 13 5 20 10
22 gH 84 19 9 16 4
27 Glycoprotein 35 5 1 8 2
39 gM 44 16 4 11 2
47 gL 19 17 2 11 2
A8 Putative glycoprotein 75 0c 0 2 1
Capsid proteins
17 SCAF/PRO 59 19 5 8 2
25 Major capsid protein 154 49 40 41 33
26 TRI-2 35 29 4 21 4
62 TRI-1 37 58 9 21 3
Tegument proteins
3 FGARAT 154 30 21 32 18
19 Tegument 62 16 3 5 3
33 Tegument 38 47 5 28 2
38 Tegument (role in egress) 7 72 2 69 2
52 Tegument (role in egress) 15 37 2 33 2
63 Tegument 108 14 4 10 5
64 Tegument 292 18 23 16 13
75 FGARAT 148 11 8 16 11
Virion-associated proteins
10 Unknown function 46 0 0 14 3
21 Thymidine kinase 64 23 8 30 10
45 Unknown function 26 4 1 0 0
54 dUTPase 34 23 8 18 2
59 Processivity factor 46 22 4 12 2
Host proteins
Actin 56 11 49 7
Annexin A2 44 8 42 9
Annexin I 23 3 28 4
Histone 2B 35 3 35 3
Histone 4 42 4 40 4
Pyruvate kinase 9 3 25 7
a Virus and host proteins were identified using MS/MS data according to the criteria described for proteomic analysis in Materials and Methods.
b The percent coverage and number of peptides were derived from MASCOT output.
c The “0” indicates that no peptides meeting the described criteria were reproducibly identified from this ORF in this virus.
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genome annotation, and (ii) to determine whether structural
differences existed between the attenuated and virulent forms
of AlHV-1. Sucrose-gradient purified virus preparations were
fractionated by SDS-PAGE, and peptides from serial gel slices
were analyzed by LC-ESI–MS/MS. This qualitative analysis
identified five herpesvirus-conserved envelope glycoproteins,
one AlHV-1 “unique” glycoprotein, eight tegument protein
candidates, four capsid components, and five nonstructural
virus proteins.
Similarities with other rhadinoviruses. Previous analysis of
the AlHV-1 genome had identified strong similarities between
the genomic organization of AlHV-1 and that of other mem-
bers of the Rhadinovirus genus of the gammaherpesvirus sub-
family (6, 11). With the exception of ORF28, which has no
homologue in AlHV-1 or OvHV-2 (11, 14), only gN (ORF53)
was not found in either attenuated or virulent AlHV-1, but it
has been consistently identified in published studies as a com-
ponent of the gammaherpesvirus virion (23, 38).
ORF53 encodes a type 1 membrane protein (gN) that is one
of five glycoproteins (gB, gH, gL, and gM being the others)
that are conserved throughout the herpesvirus family. Studies
on HHV-8 and EBV have shown that gN is dependent on the
expression of gM for its processing and is found in the virion in
a complex with gM (16, 17). Since mature gM was identified in
both attenuated and virulent AlHV-1 particles, it is likely that
gN is also a component of this virus. The failure to detect
peptides corresponding to gN may relate to its size. Based on
the molecular mass markers, the SDS-PAGE separation re-
ported here resolved virion proteins between 250 and 16 kDa
(Fig. 1). Without posttranslational modification, the predicted
molecular mass of mature AlHV-1 gN is 8.8 kDa, whereas the
native EBV gN has a mass of 15 kDa (17), suggesting that the
AlHV-1 gN may have been lost during electrophoresis.
Alternatively, failure to detect peptides derived from gN
may indicate that peptides from gN did not ionize efficiently by
ESI. Supporting evidence for this is provided by the observa-
FIG. 2. Glycoprotein B-specific peptides from both attenuated and virulent particles were identified in two distinct bands that corresponded
to N- and the C-terminal fragments of gB. Tryptic peptides identified from the 80-kDa band are shown in boldface, while peptides identified from
the 50-kDa band are shown in boldface and underlined. A furin cleavage site, RQRR (shaded in gray), marks the likely boundary between the N-
and the C-terminal domains of the protein.
FIG. 3. A single peptide from A8, DENLYVLAQIPALEGHK, with a Mowse score of 55, was identified by MASCOT from the virulent C500
virion preparation. The tryptic peptide DENLYVLAQIPALEGHK (residues 272 to 290), shaded in gray, is located centrally in the predicted A8
polypeptide sequence. Potential N-glycosylation sites are shown in boldface italics. Potential O-glycosylation sites are shown underlined.
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tion that gN in the HHV-8 and EBV particles was identified by
one C-terminal peptide (38, 15). Furthermore, identification of
gN within the EBV particle required the virion to be treated
prior to analysis by deglycosylation enzymes (15). In the
present study, deglycosylation was not carried out. Analysis of
the predicted amino acid sequence of mature AlHV-1 gN
identified only four tryptic peptides with masses from 547 to
3,560 mass units. One peptide is predicted to contain both
N-linked and O-linked glycosylation sites. It is therefore pos-
sible that a combination of posttranslational modification and
the small number of tryptic peptides available could also pre-
vent the detection of AlHV-1 gN.
Proteins encoded by ORF23, ORF35, and ORF42 were re-
ported to be tegument proteins in rhesus monkey rhadinovirus
(RRV [23]). Single spectra corresponding to ORF23 and
ORF42 were identified in only one attenuated virus prepara-
tion, so these proteins were not considered to be definite virion
components. It is possible that the ORF23-, ORF35-, and
ORF42-encoded proteins are not abundant in the tegument or
that peptides derived from these proteins did not ionize effi-
ciently by ESI. Indeed, these proteins were not identified in
analyses of EBV, HHV-8, or murine gammaherpesvirus 68
(MHV-68) virions (5, 15, 38). The analyses of HHV-8 and
MHV-68 virions were, however, based on excision of promi-
nent bands from polyacrylamide gels and therefore have the
potential to miss less-abundant proteins. The full chromato-
graphic separation of RRV (23) and the systematic analysis of
entire gel lanes described here may be more suited to the
detection of such proteins.
Six cellular proteins were identified in association with at-
tenuated and virulent AlHV-1 virions. Of these, actin, annexin
(I/A2) and pyruvate kinase have previously been identified in
association with rhadinovirus virions (5, 38). Bovine protein
sequence entries are not as well represented as other species,
so it is possible that some virus-associated host proteins may
not have been identified from MS data. Equivalent amounts of
the annexins and histones, based on the number of peptides
detected, were observed in the attenuated and virulent
AlHV-1 virions. However, differences were observed in the
number of peptides detected for actin and pyruvate kinase
between the two forms of the AlHV-1 virions (Table 1). This
may reflect differences in the assembly of the two AlHV-1
particle types or suggest that these molecules are nonspecifi-
cally included in assembled virions.
Only two proteins were detected in AlHV-1 that were not
found in proteomic analyses of other gammaherpesviruses, A8
and ORF10. Interestingly, spectra for these two proteins were
observed in the virulent AlHV-1 preparations but not in the
attenuated virus. A8 is in a region that is potentially affected by
rearrangements leading to attenuation (37), while there is no
evidence to suggest these genomic changes involve the ORF10
gene.
A7, A8, and A10. Analysis of the genome of tissue culture-
attenuated AlHV-1 C500 predicted that genomic rearrange-
ments might dysregulate or abrogate the expression of putative
glycoproteins A7, A8, and A10 (34). Recent sequencing of
other livestock gammaherpesviruses has shown that all three
genes have homologues in the MCF virus OvHV-2 (14), while
homologues of A7 and A8 are found in the sequenced segment
of porcine lymphotropic herpesvirus-1 (12).
A7 has sequence similarity to its positional analogue in
EBV, BZLF2. This gene encodes gp42, which forms a complex
with gH and gL and interacts with HLA-DR, facilitating infec-
tion of B cells (30). EBV gp42 is, however, dispensable for
infection of epithelial cells (34). Stoichiometric analysis of
EBV particles has shown gH and gL to be more abundant than
gp42, indicating that a proportion of particles produced during
EBV infection naturally lack or contain low levels of gp42 (34).
Analysis of the composition of EBV virions using LC-ESI–
MS/MS analysis identified the presence of a significant number
of peptides corresponding to gp42 within the virus particle.
Furthermore, identification of gp42 was not dependent on
deglycosylation of the EBV virion prior to analysis (15). In
contrast, peptides corresponding to A7 were not identified in
either attenuated or virulent AlHV-1 virions. It is feasible that
A7 was not detected because its peptides were unsuitable for
detection by LC-ESI–MS/MS due to their size, amino acid
composition, or posttranslational modification. Alternatively,
the lack of A7 in AlHV-1 virion preparations may reflect low
levels of A7 expression within the cell line used to propagate
AlHV-1. Further investigations, dependent on the develop-
ment of suitable reagents, are required to determine whether
A7 is indeed a virion component and what role it plays, if any,
in the attenuation of AlHV-1.
A8 is a positional homologue of genes encoding EBV gp220/
350, HHV-8 K8.1, and MHV-68 gp150. These glycoproteins
have been implicated in the binding of host cell receptors (31).
A8 was identified by the same, single peptide in both prepa-
rations of purified virulent virions, derived from a gel slice with
an estimated mass of 150 kDa (Fig. 1). A8 is predicted to be
highly glycosylated (Fig. 3), so the difference between the pre-
dicted mass (75 kDa) and the mass observed here (150 kDa;
Fig. 1) is likely to be a consequence of posttranslational mod-
ification or, like gM, protein aggregation. A high level of gly-
cosylation may also explain the identification of only a single
peptide from A8. Only about half of the 30 predicted tryptic
cleavage products of A8 are free of predicted N-linked or
O-linked glycosylation, with the nonglycosylated peptides be-
ing restricted to two areas: one central area of about 120
residues including the detected peptide, DENLYVLAQIPAL
EGHK, and a second area encompassing the C-terminal 90
residues. The size and amino acid composition of the individ-
ual peptides may further restrict which peptides can be de-
tected.
Supporting evidence for this view was found during analysis
of the A8 homolog, Ov8 from OvHV-2, expressed as a soluble
recombinant protein in mammalian cells. Proteomic analysis of
a gel band containing microgram quantities of purified Ov8
identified only three Ov8-specific spectra. The corresponding
three peptides were derived from the central area of the Ov8
protein sequence that is equivalent to the position of the iden-
tified peptide from A8 (J. P. Stewart, unpublished data).
The modification of envelope glycoprotein genes in attenu-
ation has been observed in the alphaherpesvirus equine her-
pesvirus 1 (EHV-1). Studies on culture-adapted forms of
EHV-1 have shown that attenuation results from the expres-
sion of a truncated form of a single glycoprotein, gp2 (29).
However, truncation of A8 was not observed in the attenuation
of AlHV-1 (37). The observed rearrangements in AlHV-1 in-
volve the adjacent A7 gene and suggest that A8 may be dys-
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regulated by rearrangements involving its promoter (within
A7) or that it may be deleted.
EBV gp350/220 has been demonstrated to mediate attach-
ment to and infection of B lymphocytes (22, 32, 33). Given that
the position of A8 in the AlHV-1 genome is equivalent to
genes encoding EBV gp350/220, HHV-8 K8.1, and MHV-68
gp150, A8 may act in the same way as these glycoproteins to
mediate the attachment of AlHV-1 to lymphocytes. Dysregu-
lation or abrogation of A8 should therefore be accompanied by
a concomitant loss of binding of the virus to lymphocytes.
Initial studies of virus-cell interactions indicate that binding of
attenuated AlHV-1 to peripheral blood mononuclear cells is
significantly less efficient than binding of virulent virus, sug-
gesting that the attenuated virus may have a defect in binding
to lymphocytes (I. Dry, G. C. Russell, D. M. Haig, and J. P.
Stewart, unpublished data).
In contrast to A7 and A8, no clear sequence or positional
glycoprotein homolog to A10 has been identified in other gam-
maherpesviruses. Peptides from the predicted glycoprotein
A10 were not identified in any of the AlHV-1 virion prepara-
tions, suggesting that A10 is not an abundant virion-associated
glycoprotein. Further research is needed to determine whether
A10 is, in fact, a component of the infectious virus. Recent
analysis of the genome of OvHV-2 has identified multiple
nuclear localization signals in addition to a transmembrane
anchor in Ov10, the homologue of A10 (14). This may mean
that Ov10 and A10 play a nonstructural role in MCF virus
infection and are not viral components.
ORF10. Three peptides from ORF10 were identified in two
independent preparations of virulent AlHV-1, suggesting ei-
ther that its expression was high enough for incorporation into
the virion in only the virulent virus or that it is a genuine virion
component that was not detected in the attenuated virion.
ORF10 is a member of a family of herpesvirus genes that
encode dUTPase-related proteins (9). In gammaherpesviruses
this family also includes the ORF11 gene, whose product ap-
peared to be incorporated into the particles of HHV-8 (38).
ORF10 was previously detected in a rhesus monkey rhadino-
virus particle (23) but was found in only one analysis; ORF10
was not designated as a component of this virus. No evidence
has been presented to suggests that the orthologs of ORF10
are present in the virions of HHV-8 and MHV-68 (4, 38).
The region of the genome in which the ORF10 gene is
located was not reported to be affected by the genomic rear-
rangements associated with the attenuation of A1HV-1 (37).
The presence of this dUTPase-related protein within only the
virulent form of the AlHV-1 particle suggests that the ORF10-
encoded protein is included in the AlHV-1 virion via interac-
tions with other protein(s) whose expression is abrogated or
dysregulated by the rearrangements. Research on other gam-
maherpesviruses has shown that deletion of the region of the
genome encompassing ORF10 and ORF11 has no effect on the
ability of these viruses to grow in culture (20, 24), although
ORF11 deletion viruses were found to have reduced lytic rep-
lication in vivo (4).
The recent development of a BAC of AlHV-1 (10) will
enable the potential roles of genes such as A8 and ORF10 in
the pathogenesis and attenuation of AlHV-1 to be studied in
vitro and in vivo. Development of reagents, including recom-
binant viral antigens and antibodies to the viral proteins iden-
tified in the present study, may also provide important infor-
mation about the role of the viral proteins in both host
infection and the development of MCF in susceptible species.
Proteins that constitute the herpesvirus virion play func-
tional roles both in the assembly and egress of the virus and in
the initiation of infection. The qualitative methods used in the
present study may not be sufficiently sensitive to detect subtle
changes in the composition or assembly of the virion. However,
few differences between attenuated and virulent particles were
observed, suggesting that AlHV-1 attenuation may be medi-
ated through changes in the expression of proteins that are not
virion components, e.g., the transcription factors A6 or
ORF50. Construction of a detailed map of the attenuated
AlHV-1 C500 virus, based on complete DNA sequencing, may
provide further clues to the mechanism of AlHV-1 attenua-
tion.
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